{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:16:26Z","timestamp":1793038586986,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The lung cancer (LC) treatment landscape has drastically expanded with the arrival of immunotherapy and targeted therapy. This new variety of treatment options, each with its own characteristics, raises uncertainty regarding the key aspects affecting patients\u2019 health-related quality of life (HRQL). The present qualitative study aimed to investigate how LC patients perceive their HRQL and the factors that they consider to be most influential in determining their HRQL.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This qualitative research incorporates four focus group discussions, with six LC patients in each group. In total, 24 stage III and IV LC patients were included in the discussions, with Italian (<jats:italic>n<\/jats:italic> = 12) and Belgian (<jats:italic>n<\/jats:italic> = 12) patients, age range: 42\u201378, median age = 62 (IQR = 9.3\u00a0years), SD = 8.5; 62% men. Using thematic analysis, transcripts and notes from the FGDs were analyzed using NVivo software (edition 12).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Three main themes capturing determinants of HRQL were identified. First, patients agreed on the importance of physical aspects (symptoms and side-effects) in determining their HRQL. In particular, skin conditions, nausea, fatigue, risk of infections, sensory abnormalities, pain, and changes in physical appearance were highlighted. Second, patients worried about psychological aspects, negatively impacting their wellbeing such as uncertainties regarding their future health state, and a lower degree of autonomy and independence. Third, patients underlined the importance of social aspects, such as communication with healthcare providers and social interaction with friends, family and peers.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study demonstrates that physical, psychological, and social aspects are key factors driving LC patients\u2019 HRQL. Gaining a better understanding of how LC patients perceive their HRQL and how it is affected by their illness and therapy will aid patient-centric decision-making across the drug life cycle, by providing stakeholders (drug developers, regulators, reimbursement bodies, and clinicians) insights about the treatment and disease aspects of importance to LC patients as well as the unmet needs LC patients may have regarding available treatment modalities. Finally, this study underscores a need for individual treatment decision-making that is considerate of uncertainties among LC patients about their future health state, and ways for improving communication between healthcare providers and patients to do so.<\/jats:p>","DOI":"10.3389\/fphar.2021.710518","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T06:04:54Z","timestamp":1632377094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Key Determinants of Health-Related Quality of Life Among Advanced Lung Cancer Patients: A Qualitative Study in Belgium and Italy"],"prefix":"10.3389","volume":"12","author":[{"given":"Rosanne","family":"Janssens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Arnou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Schoefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Petrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clizia","family":"Cincidda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ongaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Oliveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith Y.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vandevelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiaan","family":"Nackaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"B3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fphar.2017.00339","article-title":"The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature","volume":"8","author":"Bennett","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2010.05.001","article-title":"Patients' Preferences for Chemotherapy in Non-small-cell Lung Cancer: a Systematic Review","volume":"69","author":"Blinman","year":"2010","journal-title":"Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2017.09.011","article-title":"Patient-reported Outcome Measures (PROMs) in the Management of Lung Cancer: A Systematic Review","volume":"113","author":"Bouazza","year":"2017","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B7","first-page":"588","article-title":"Brief Questions to Identify Patients with Inadequate Health Literacy","volume":"36","author":"Chew","year":"2004","journal-title":"Fam. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hec.1739","article-title":"Using Qualitative Methods for Attribute Development for Discrete Choice Experiments: Issues and Recommendations","volume":"21","author":"Coast","year":"2012","journal-title":"Health Econ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fphar.2019.00230","article-title":"Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing","volume":"10","author":"Dong","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"622154","DOI":"10.3389\/fpubh.2021.622154","article-title":"Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients","volume":"9","author":"Durosini","year":"2021","journal-title":"Front. Public Health"},{"key":"B11","unstructured":"EORTC QLQ-C30-LC132018"},{"key":"B12","unstructured":"Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale1995"},{"key":"B13","unstructured":"FACT-LCS\n            Fact-Lcs\n          1995"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e20190420","DOI":"10.36416\/1806-3756\/e20190420","article-title":"Role that Anorexia and Weight Loss Play in Patients with Stage IV Lung Cancer","volume":"46","author":"Franceschini","year":"2020","journal-title":"J. Bras Pneumol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.12688\/f1000research.11902.1","article-title":"Advancing Psychosocial Care in Cancer Patients","volume":"6","author":"Grassi","year":"2017","journal-title":"F1000Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpainsymman.2019.03.015","article-title":"Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review","volume":"58","author":"HallSinghal","year":"2019","journal-title":"J. Pain Symptom Manage."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e023672","DOI":"10.1136\/bmjopen-2018-023672","article-title":"Coping, Mood and Health-Related Quality of Life: a Cross-Sectional Study in Chinese Patients with Advanced Lung Cancer","volume":"9","author":"He","year":"2019","journal-title":"BMJ Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2169\/internalmedicine.44.107","article-title":"Patients Preferences in Chemotherapy for Advanced Non-small-cell Lung Cancer","volume":"44","author":"Hirose","year":"2005","journal-title":"Intern. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pon.1450","article-title":"Patient Willingness to Undergo Chemotherapy and Thoracic Radiotherapy for Locally Advanced Non-small Cell Lung Cancer","volume":"18","author":"Hirose","year":"2009","journal-title":"Psychooncology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12911-019-0875-z","article-title":"Opportunities and Challenges for the Inclusion of Patient Preferences in the Medical Product Life Cycle: a Systematic Review","volume":"19","author":"Janssens","year":"","journal-title":"BMC Med. Inform. Decis. Mak"},{"key":"B21","volume-title":"Patient Preferences in the Medical Product Life Cycle: What Do Stakeholders Think? Semi-structured Qualitative Interviews in Europe and the USA","author":"Janssens","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/1740774519836991","article-title":"Patient Reported Outcomes in Anti-PD-1\/pd-L1 Inhibitor Immunotherapy Registration Trials: FDA Analysis of Data Submitted and Future Directions","volume":"16","author":"King-Kallimanis","year":"2019","journal-title":"Clin. Trials"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/pon.3155","article-title":"Uncertainty and Psychological Adjustment in Patients with Lung Cancer","volume":"22","author":"Kurita","year":"2013","journal-title":"Psychooncology"},{"key":"B24","volume-title":"Qualitative Research Analysis: The NIHR RDS for the East Midlands","author":"Lacey","year":"2007"},{"key":"B25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1365-2354.2009.01101.x","article-title":"Health-related Quality of Life in Lung Cancer Patients in Serbia: Correlation with Socio-Economic and Clinical Parameters","volume":"19","author":"Maric","year":"2010","journal-title":"Eur. J. Cancer Care (Engl)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/JMDH.S122383","article-title":"Value as the Key Concept in the Health Care System: How it Has Influenced Medical Practice and Clinical Decision-Making Processes","volume":"10","author":"Marzorati","year":"2017","journal-title":"J. Multidiscip Healthc."},{"key":"B27","volume-title":"Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. U.S. Department of Health and Human Services. Food and Drug Administration","author":"Patient Preference Information \u2013 Voluntary Submission","year":"2016"},{"key":"B28","volume-title":"Collecting Comprehensive and Representative Input - Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders - GUIDANCE. U.S. Department of Health and Human Services Food and Drug Administration CfDEaRC","author":"Patient-Focused Drug Development","year":"2018"},{"key":"B29","doi-asserted-by":"publisher","first-page":"602112","DOI":"10.3389\/fphar.2021.602112","article-title":"What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences","volume":"12","author":"Petrocchi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B30","unstructured":"Patient Preferences\n            Prefer\n          2020"},{"key":"B31","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/bmjspcare-2013-000589","article-title":"Quality of Life, Support and Smoking in Advanced Lung Cancer Patients: a Qualitative Study","volume":"6","author":"Rowland","year":"2016","journal-title":"BMJ Support. Palliat. Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ecc.12425","article-title":"Preferences of Lung Cancer Patients for Treatment and Decision-Making: a Systematic Literature Review","volume":"25","author":"Schmidt","year":"2016","journal-title":"Eur. J. Cancer Care (Engl)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2147\/PPA.S138863","article-title":"Therapy Preferences of Patients with Lung and colon Cancer: a Discrete Choice experiment","volume":"11","author":"Schmidt","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","article-title":"Methods for Exploring and Eliciting Patient Preferences in the Medical Product Lifecycle: a Literature Review","volume":"24","author":"Soekhai","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40271-020-00434-7","article-title":"Quantitative Preferences for Lung Cancer Treatment from the Patients' Perspective: A Systematic Review","volume":"13","author":"Sugitani","year":"2020","journal-title":"Patient"},{"key":"B37","first-page":"5","volume-title":"ICH Reflection Paper on Proposed ICH Guideline Work to advance Patient Focused Drug Development","author":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (Ich)","year":"2020"},{"key":"B1","unstructured":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims2006"},{"key":"B38","volume-title":"Patient Preference Information \u2013 Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling","author":"Us Food and Drug Administration","year":"2016"},{"key":"B2","volume-title":"Patient Preference-Sensitive Areas: Using Patient Preference Information in Medical Device Evaluation","author":"US Food and Drug Administration","year":"2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3389\/fonc.2019.00715","article-title":"Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review","volume":"9","author":"Van Der Weijst","year":"2019","journal-title":"Front. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3389\/fphar.2019.01395","article-title":"Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study","volume":"10","author":"van Overbeeke","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drudis.2018.09.015","article-title":"Factors and Situations Influencing the Value of Patient Preference Studies along the Medical Product Lifecycle: a Literature Review","volume":"24","author":"van Overbeeke","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1007\/s00520-021-05989-1","article-title":"A Qualitative Study of Online Support Communities for Lung Cancer Survivors on Targeted Therapies","volume":"29","author":"Walsh","year":"2021","journal-title":"Support Care Cancer"},{"key":"B43","volume-title":"Factors and Situations Affecting the Value of Patient Preference Studies: Semi-structured Interviews in Europe and the US Frontiers in Pharmacology","author":"Whichello","year":"2019"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.710518\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T06:05:14Z","timestamp":1632377114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.710518\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":43,"alternative-id":["10.3389\/fphar.2021.710518"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.710518","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"article-number":"710518"}}